Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tevogen Bio Holdings Inc. - Common Stock
(NQ:
TVGN
)
1.120
+0.160 (+16.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tevogen Bio Holdings Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 10, 2024
Via
Benzinga
Why BloomZ Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
October 10, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 09, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 08, 2024
Via
Benzinga
Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation
October 08, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
September 24, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
September 10, 2024
Via
Benzinga
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
August 26, 2024
Via
Benzinga
Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
August 22, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
August 15, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
August 15, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health
August 14, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
August 09, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
July 11, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
July 10, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
June 26, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility
July 08, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
June 25, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
June 18, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Set to Join Russell 3000® Index
June 12, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 12, 2024
Via
Benzinga
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
June 11, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
June 07, 2024
Via
Benzinga
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
June 07, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
June 06, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
June 06, 2024
Via
Benzinga
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
June 06, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
TVGN Stock Earnings: Tevogen Bio Holdings Reported Results for Q1 2024
May 30, 2024
Tevogen Bio Holdings just reported results for the first quarter of 2024.
Via
InvestorPlace
Tevogen Bio Reports First Quarter 2024 Financial Results
May 29, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
May 21, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.